Yosemite is proud to lead the $20M investment in Sage Care. Justin Ho, Chris Blumenberg, and Caesar Djavaherian started Sage Care to change how patients navigate to clinicians using both intelligent AI agents and advanced optimization and matching. As our Investor Matt Bettonville said, "Sage Care has the unique vision to not only replace legacy IT systems with AI, but to totally reinvent the front office of healthcare around this technology. We believe they can take away the frustration of dealing with healthcare and help reduce crucial times to diagnose and treat patients who need it most." With Chris and Justin's experience building optimization and routing algorithms at Uber and then co-founding RideOS together paired with Caesar's clinical expertise as an emergency medicine physician and co-founder at Carbon Health, we felt this was the perfect team to reinvent the entire intake and triage process. Congratulations to the team at Sage Care. https://lnkd.in/g6EU923U
Yosemite
Venture Capital and Private Equity Principals
San Francisco, CA 4,965 followers
Yosemite aims to make cancer non-lethal within our lifetime
About us
Yosemite is an oncology-focused venture fund investing in biotech and healthcare innovations to make cancer non-lethal. Founded by Reed Jobs in 2015, the fund originated with Emerson Collective before becoming independent in 2023. Yosemite’s unique investment model restructures the traditional academic-industry partnership by utilizing philanthropic capital to seed pioneering scientific research, enabling Yosemite to strengthen collaborations with academic institutions and provide access to investable science earlier in the commercialization pipeline.
- Website
-
yosemite.co
External link for Yosemite
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
Get directions
San Francisco, CA, US
Employees at Yosemite
Updates
-
Yosemite is excited to lead the $8.4M investment in Fourier Health and back the team’s vision to reduce time needed to treat patients most in need of specialized care. Fourier Health is redefining how unstructured data is processed and summarized - using clinician-in-the-loop AI to eliminate administrative burden, accelerate patient intake, and improve access to care. Founded by James Lloyd (formerly Founder and CTO at Redox) and Christopher Lee (formerly Co-Founder and COO at InfiniteMD), the team is building the infrastructure that finally makes fragmented healthcare data usable. Congratulations to the team at Fourier! https://lnkd.in/e_cHNcBg
-
Digital health is a core part of Yosemite’s investment strategy to foster transformational change across oncology and the medical system. Yosemite’s Matt Bettonville and Reed Jobs joined the The Heart of Healthcare Podcast to talk about Yosemite’s work in the space and touched on a key moment that guided their philosophy of supporting wide-ranging digital health interventions.
Investor Matt Bettonville joins us to explore a bold new frontier in cancer care—where software can outperform pharmaceuticals. Alongside Reed Jobs at Yosemite, Matt is backing digital health tools that have shown survival outcomes rivaling, and in some cases surpassing, traditional cancer drugs. Yosemite’s hybrid model of venture investing and grantmaking is designed to fast-track innovation and ensure it reaches the people who need it most. We dive into: 📊 How digital interventions are reshaping survival curves 💸 The economics of drug development vs. digital therapeutics 🧬 Synthetic control arms and the future of clinical trials 🔍 Early detection tech—from liquid biopsies to at-home diagnostics 🌐 Why global leadership in healthcare innovation is up for grabs Listen here: Apple: https://lnkd.in/gRkQM9aJ Spotify: https://lnkd.in/gy-C_fBD #DigitalTherapeutics #CancerInnovation #YosemiteFund #NextGenCures #EndCancer #HealthTech #TheHeartOfHealthcare
-
Proud of the team at Daymark Health for changing the cancer care experience through their recently announced partnership with BCBS RI and raising their Series A. Thrilled to have Healthier Capital and The Blue Venture Fund join the Board.
💙 At Daymark Health, we’ve always believed that exceptional cancer care is about more than what happens in the clinic. Patients and families spend hundreds of hours outside hospital walls — navigating uncertainty, stress, and everyday life while undergoing treatment. Too often, the system leaves them to carry that burden alone. That’s the gap Daymark was created to fill. We help meet our patients’ clinical, social, and mental health needs both virtually and in the home, in collaboration with oncologists and primary care providers. And today, we’re proud to share two milestones that bring us closer to that vision: ✨ We’ve raised our Series A funding round – led by Healthier Capital with The Blue Venture Fund with participation from Maverick Ventures, Yosemite, and Oncology Ventures. This capital will give us the resources to expand our team and build the kind of support system every patient deserves. 🤝 We’ve teamed up with our first health plan, offering in-network care to over 400k members with 2,500 in active treatment and ensuring they can all access comprehensive, personalized cancer care where they need it most. (More here: https://lnkd.in/giEk8wtA) These aren’t just business milestones – they’re steps toward a future where no one faces cancer alone. Where patients have care teams who walk with them not only through treatment, but through the day-to-day challenges and moments in between. To our investors, partners, and especially to the patients and families who inspire us every day: thank you for believing that better is possible. This is just the beginning. Read more about our news here 👉 https://lnkd.in/gByFrriR
-
Yosemite’s mission is clear: making cancer non-lethal in our lifetime. To get there, we must protect and expand NIH funding. That’s why we joined Stand Up To Cancer and over 400 organizations in Washington, D.C. for the Rally for Medical Research — a united call to ensure lifesaving research can continue without interruption. Read more on why protecting NIH funding matters: https://lnkd.in/gWaGj9f5 #FundNIH #RallyMedRes #MoreProgressMoreHope
-
Congratulations to the Skyhawk Therapeutics team on achieving a major clinical milestone in Huntington’s disease. These early results highlight meaningful progress toward potential new treatments for patients facing this devastating condition.
Excited to share our first interim data in our Phase 1 for Huntington's patients, showing 62% lowering of mutant huntingtin protein ~ check out the release here! https://lnkd.in/erVfdjcS